Search clinical trials for: CD19 hsCAR-T

Total 757 results

University of Western Ontario, Canada
Arthrex, Inc.

Unknown

Autologous Conditioned Plasma (ACP) for Patients With Plantar Fasciitis

Chronic Plantar Fasciitis

Canada
Second Affiliated Hospital, School of Medicine,...

Recruiting

Sequential Low-dose Decitabine With PD-1/CD28 CD19 CAR-T in Relapsed or Refractory B-cell Lymphoma

Objective Response Rate

China
Shanxi Province Cancer Hospital
Shanghai Ultra-T Immune Therapeutics Co. LTD

Recruiting

Targeting CD19 and CD22 CAR-T Cells Immunotherapy in Patients With Relapsed or Refractory Acute B Lymphocytic Leukemia

Acute Lymphocytic Leukemia， B-Cell

China
He Huang
Nanjing Bioheng Biotech Co., Ltd.

Recruiting

A Study of CT-RD06 Cell Injection in Patients With Relapsed or Refractory CD19+ B-cell Hematological Malignancy

Non-Hodgkin's Lymphoma | Acute Lymphoblastic Leukemia

China
Henan Cancer Hospital
The Beijing Pregene Science and Technology Company, Ltd.

Unknown

The Safety and Efficacy of CART-19 Cells in Relapse and Refractory Patients With CD19+ B-cell Lymphoma

B Cell Lymphoma

China
National Cancer Institute (NCI)

Recruiting

Trial of Anti-CD19 and Anti-CD20 Bicistronic Chimeric Antigen Receptor T Cells for Treating B-Cell Malignancies

Lymphoma, B-Cell | Chronic Lymphocytic Leukemia | B-Cell Chronic Lymphocytic Leukemia

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI); Takeda

Recruiting

IVIG for Infection Prevention After CAR-T-Cell Therapy

Lymphoma

United States
Shanxi Province Cancer Hospital
Novatim Immune Therapeutics (Zhejiang) Co., Ltd.

Recruiting

Targeting CD19 and CD22 CAR-T Cells Immunotherapy in Patients With Relapsed or Refractory B Cell Lymphoma

Lymphoma, B-Cell

China
Sabz Biomedicals
Gene Therapy Research Center, Shariati Hospital, Tehran University of Medical... and other collaborators

Not yet recruiting

CD19 Targeted CAR T Cell Therapy in Patients With Relapsed/ Refractory B Cell Acute Lymphoblastic Leukaemia (ALL)

Relapsed B Cell Acute Lymphoblastic Leukemia (ALL) | Refractory B Cell Acute Lymphoblastic Leukemia (ALL)

Iran, Islamic Republic of
Wuhan Sian Medical Technology Co., Ltd
Wuhan Union Hospital, China; Xiangyang Central Hospital; Jingzhou Central Hospital and other collaborators

Recruiting

Humanized CD19 Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy in Treating Patients With B-cell Malignancies

B Cell Lymphoma | Acute Lymphoblastic Leukemia

China
Federal Research Institute of Pediatric Hematology...

Active, not recruiting

Bispecific CD19/CD22 CAR-T for Treatment of Children and Young Adults With r/r B-ALL

B-ALL

Russian Federation
Affimed GmbH

Terminated

Safety Study to Assess AFM11 in Patients With Relapsed and/or Refractory CD19 Positive B-cell NHL

Refractory B-Cell Non-Hodgkin Lymphoma | Relapsed B-Cell Non-Hodgkin Lymphoma

United States, Czechia, Germany, Poland
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Withdrawn

CAR.CD19-CD28-zeta-2A-iCasp9-IL15-Transduced Cord Blood NK Cells, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Participants With B-cell Lymphoma

Mantle Cell Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Recurrent Follicular Lymphoma | Refractory Follicular Lymphoma | CD19 Positive

United States
Sumithira Vasu
National Cancer Institute (NCI)

Recruiting

Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies

Recurrent B Acute Lymphoblastic Leukemia | Refractory B Acute Lymphoblastic Leukemia | Refractory Chronic Lymphocytic Leukemia | Recurrent Non-Hodgkin Lymphoma | Refractory Non-Hodgkin Lymphoma | Recurrent Acute Lymphoblastic Leukemia | Refractory Acute Lymphoblastic Leukemia | Recurrent High Grade... and other conditions

United States
Memorial Sloan Kettering Cancer Center
Actinium Pharmaceuticals

Recruiting

Iomab-ACT: A Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma

Diffuse Large B-cell Lymphoma | B-ALL | DLBCL | DLBCL, Nos Genetic Subtypes | B ALL | Dlbcl-Ci | DLBCL Unclassifiable | DLBCL Activated B-Cell Type | DLBCL Germinal Center B-Cell Type | HGBL | HGBL, Nos

United States
Changhai Hospital
Rui Therapeutics

Not yet recruiting

An Exploratory Clinical Study of Anti-CD19 CAR NK Cell (KN5501) in the Treatment of Relapsed/Refractory Immune Nephropathy

Nephropathy
University of Florida
Florida Department of Health

Recruiting

Alpha/Beta T Cell and CD19+ B Cell Depletion in Allogeneic Stem Cell Transplantation in Patients With Malignant Diseases

Lymphoma, Non-Hodgkin | Acute Myeloid Leukemia | Myelodysplastic Syndromes | Juvenile Myelomonocytic Leukemia | Acute Lymphoblastic Leukemia | Chronic Myeloid Leukemia | Lymphoma, Hodgkin

United States
Amgen Research (Munich) GmbH

Completed

Phase II Study of the BiTE® Blinatumomab (MT103) in Patients With Minimal Residual Disease of B-precursor Acute Lymphoblastic Leukemia (ALL)

Acute Lymphoblastic Leukemia

Germany
Bruce Cree
Kyverna Therapeutics

Recruiting

A Study of KYV-101, a CD19 CAR T Cell Therapy, in Participants With Treatment Refractory Progressive Multiple Sclerosis

Progressive Multiple Sclerosis

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Modified Immune Cells (CD19 CAR T Cells) and Acalabrutinib for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

Recurrent Mantle Cell Lymphoma | Refractory Mantle Cell Lymphoma

United States
Institute of Hematology & Blood Diseases Hospital...
Nanjing Legend Biotech Co.

Active, not recruiting

A Triple-targeted Cell Preparation Targeting CD19/CD20/CD22 in Patients With Relapsed/Refractory B-cell Acute Lymphocytic Leukemia

Acute Lymphocytic Leukemia

China
Chinese PLA General Hospital

Withdrawn

Treatment of Relapsed and/or Refractory AQP4-IgG Seropositive NMOSD by Tandem CAR T Cells Targeting CD19 and CD20

Neuromyelitis Optica Spectrum Disorder

China
Crystal Mackall, MD

Recruiting

Phase I Dose Escalation Study of CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies

Recurrent Adult Acute Lymphoblastic Leukemia | Recurrent Childhood Acute Lymphoblastic Leukemia | B Acute Lymphoblastic Leukemia | Philadelphia Chromosome Positive | Refractory Acute Lymphoblastic Leukemia | Minimal Residual Disease | CD19 Positive

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

Genetically Modified T-cell Infusion Following Peripheral Blood Stem Cell Transplant in Treating Patients With Recurrent or High-Risk Non-Hodgkin Lymphoma

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma | Recurrent Adult Diffuse Small Cleaved Cell Lymphoma and other conditions

United States
AO GENERIUM

Recruiting

GNR-084 Safety and Pharmacological Characteristics in Refractory or Relapse B-cell Precursor ALL

ALL | B-precursor Acute Lymphoblastic Leukemia | GNR-084

Russian Federation
National Cancer Institute (NCI)

Recruiting

Inotuzumab Ozogamicin and Blinatumomab in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia

Recurrent B Acute Lymphoblastic Leukemia | Refractory B Acute Lymphoblastic Leukemia | B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative

United States
National Cancer Institute (NCI)

Active, not recruiting

Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin Lymphoma

Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma | Recurrent Small Lymphocytic Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell... and other conditions

United States
H. Lee Moffitt Cancer Center and Research Institute
Kite, A Gilead Company

Recruiting

Single-Arm Comprehensive Ablative Bridging Irradiation I Prior to CD19 CAR-T In High-Risk R/R LBCL

Large B-cell Lymphoma | Relapsed Non-Hodgkin Lymphoma

United States
Chinese PLA General Hospital
Peking University; EdiGene Inc.

Recruiting

TRAC and Power3 Genes Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B-NHL

Non Hodgkin's Lymphoma

China
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

CD19-Car T Cell Therapy for the Treatment of Older Adults With Acute Lymphoblastic Leukemia in First Remission

B Acute Lymphoblastic Leukemia

United States
He Huang
Nanjing Bioheng Biotech Co., Ltd.

Recruiting

A Study of CTA30X Cell Injection in Patients With Relapsed or Refractory CD19-positive B-line Hematological Malignancies

Acute Lymphoblastic Leukemia | Non-hodgkin Lymphoma

China
Caribou Biosciences, Inc.

Recruiting

CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)

Lymphoma | Lymphoma, Non-Hodgkin | B Cell Lymphoma | Non Hodgkin Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Relapsed Non Hodgkin Lymphoma | B Cell Non-Hodgkin's Lymphoma

United States, Australia, Israel
Shenzhen BinDeBio Ltd.
Xiangya Hospital of Central South University

Recruiting

A Clinical Study of CAR-T Cells Treatment for Children With CD19+/CD22+ R/R ALL and Lymphoma

Relapsed B-cell Acute Lymphoblastic Leukemia, Childhood | Refractory B-cell Acute Lymphoblastic Leukemia, Childhood | Relapsed/Refractory B-cell Lymphoma, Childhood

China
University Hospital Heidelberg

Recruiting

Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-generation CAR

Follicular Lymphoma | Mantle Cell Lymphoma | Chronic Lymphocytic Leukemia | Diffuse Large B Cell Lymphoma | Acute Lymphoblastic Leukemia, Pediatric | Acute Lymphoblastic Leukemia, Adult

Germany
Institute of Hematology & Blood Diseases Hospital
Shanghai Cell Therapy Engineering Technology Research Center Group Co., Ltd.

Unknown

Exploratory Study of CD19-targeted Chimeric Antigen Receptor T Cells(BZ019) for Relapsed and Refractory B-cell Lymphoma

Diffuse Large B Cell Lymphoma | High-grade B-cell Lymphoma | Primary Mediastinal Large B Cell Lymphoma | Transformed Lymphoma

China
Cabaletta Bio

Recruiting

RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus

Systemic Lupus Erythematosus | Lupus Nephritis

United States
Memorial Sloan Kettering Cancer Center
Dana-Farber Cancer Institute:Dana- Farber/Children's Hospital

Active, not recruiting

T-Lymphocytes Genetically Targeted to the B-Cell Specific Antigen CD19 in Pediatric and Young Adult Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia

Relapsed B-Cell Acute Lymphoblastic Leukemia

United States
St. Jude Children's Research Hospital

Active, not recruiting

Haplocompatible Transplant Using TCRα/β Depletion Followed by CD45RA-Depleted Donor Lymphocyte Infusions for Severe Combined Immunodeficiency (SCID)

Severe Combined Immunodeficiency

United States
Seattle Children's Hospital

Active, not recruiting

B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults

Melanoma | Soft Tissue Sarcoma | Carcinoma | Osteosarcoma | Ewing Sarcoma | Rhabdoid Tumor | Neuroblastoma | Retinoblastoma | Rhabdomyosarcoma | Wilms Tumor | Hepatoblastoma | Synovial Sarcoma | Desmoplastic Small Round Cell Tumor | Germ Cell Tumor | Pediatric Solid Tumor | Clear Cell Sarcoma | Malignant Peripheral Nerve Sheath...

United States
Chinese PLA General Hospital

Recruiting

TCR Reserved and Power3 Gene Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B Cell Lymphoma

Non-hodgkin Lymphoma

China
Second Affiliated Hospital, School of Medicine,...

Recruiting

Clinical Study of Cord Blood-derived CAR NK Cells Targeting CD19/CD70 in Refractory/Relapsed B-cell Non-Hodgkin Lymphoma

B-cell Non Hodgkin Lymphoma

China
Academic and Community Cancer Research United

Not yet recruiting

Epcoritamab Compared to Observation for Treating B-cell Lymphoma Patients Not in Complete Remission After CD19-directed CAR-T Therapy

Primary Mediastinal Large B-Cell Lymphoma | Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma

United States
Chimagen Biosciences, Ltd

Recruiting

First-in-Human (FIH) Trial of 1A46 in Subjects With Advanced CD20 and/or CD19 Positive B-cell Hematologic Malignancies

Non-Hodgkin's Lymphoma (Disorder) | Acute Lymphoid Leukemia, Disease (Disorder)

United States
Timothy Voorhees

Active, not recruiting

Siltuximab for the Prevention of CAR T Cell Related Cytokine Release Syndrome in Patients With CD19 Positive Non-Hodgkin Lymphoma

Non-Hodgkin Lymphoma

United States
Pinze Lifetechnology Co. Ltd.
Chinese Academy of Sciences; Navy General Hospital, Beijing

Unknown

Efficacy and Safety of PZ01 Treatment in Patients With r/r CD19+ B-cell Acute Lymphoblastic Leukemia/B Cell Lymphoma

B-cell Lymphoma | B-cell Acute Lymphoblastic Leukemia

China
Nektar Therapeutics

Recruiting

NKTR-255 vs Placebo Following CD19-directed CAR-T Therapy in Patients With Relapsed/Refractory Large B-cell Lymphoma

Non-Hodgkin Lymphoma | Relapsed/Refractory Diffuse Large B-cell Lymphoma

United States
He Huang
Nanjing Bioheng Biotech Co., Ltd.

Recruiting

A Study of CTA101 UCAR-T Cell Injection in Patients With Relapsed or Refractory CD19+ B-line Hematological Malignancy

Acute Lymphoblastic Leukemia | Non-hodgkin Lymphoma

China
Michael Pulsipher, MD

Recruiting

Conditioning SCID Infants Diagnosed Early (CSIDE)

SCID

United States, Canada
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Monoclonal Antibody Therapy in Treating Patients With Lymphoma or Leukemia

Lymphoma | Leukemia

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) for the Treatment of Intermediate or High Grade B-Cell Non-Hodgkin Lymphoma

Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | High Grade B-Cell Non-Hodgkin's Lymphoma | Intermediate Grade B-Cell Non-Hodgkin's Lymphoma

United States

Search clinical trials for: CD19 hsCAR-T

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Tanzania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations